To amend title XVIII of the Social Security Act to provide for direct payment to physician assistants under the Medicare program for certain services furnished by such physician assistants.

Medicare reimbursement, transparency, regulatory reform, Home Health (S 445, HR 1825),Veterans Administration issues, Promote Access to Diabetic Shoes (HR 1617, S. 3067), ACO assignment (HR 1160), federal mandatory education requirements for prescribing opioids, H.R. 5506 - Direct payment for PAs, Opioid and substance use disorder treatment - H.R. 6, H.R. 3692, S. 2650.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare reimbursement, transparency, regulatory reform, PA Direct Pay Act (HR 5506), Home Health (S 445, HR 1825),Veterans Administration issues, Promote Access to Diabetic Shoes (S 3067, HR 1617), Supervise cardiac and pulmonary rehab (S 1361, HR 1155), ACO assignment (HR 1160), Treat and Reduce Obesity Act (S 830, HR 1953), Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (HR 6), Palliative Care and Hospice Education and Training Act (S 693, HR 1676), Treatment of PA Education in the National Defense Authorization Act, PA Educational and Workforce Training Program Funding (FY19 L/HHS Appropriations), issues related to federal PA workforce at the Department of Veterans Affairs (FY19 Military Construction, Veterans Affairs and Related Agencies Appropriations), Addiction Treatment Access Improvement Act(HR 3692, S 2317), federal mandatory education requirements for prescribing opioids and federal workers compensation, federal limits on prescribing opioids and provisions related to medication assisted treatment (S 2456, HR 5311).

Client expense: $300,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $60,000

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $60,000

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $30,000

Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules; ESRD prospective payment system CY 2017; Quality Incentive Program PY 2020 Final Rule

Client expense: $140,000 · Firm income: Not reported

Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules; ESRD prospective payment system CY 2017; Quality Incentive Program PY 2020 Final Rule

Client expense: $140,000 · Firm income: Not reported

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $100,000

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $100,000

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); The Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R.1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The End Stage Renal Disease Choice Act (H.R. 5659); CMS 3337-ATII Medicare Program: Conditions for Coverage for End Stage Renal Disease - Third Party Payment; 21st Century Cures Act (H.R.6).

Client expense: Not reported · Firm income: $40,000

Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.

Client expense: $230,000 · Firm income: Not reported

Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.

Client expense: $230,000 · Firm income: Not reported